Hinova Pharmaceuticals Inc. News

Announcement of voluntary disclosure of clinical trial approval notice for drug clinical trial of HP560 tablets used for the treatment of myelofibrosis (myeloproliferative tumor)

Jul 24 12:00 ET

Announcement of voluntary disclosure of the clinical phase I/II trial application for HP537 for the treatment of hematological malignancies approved by the United States FDA.

Jul 7 12:00 ET

Announcement on voluntary disclosure of oral PROTAC drug HP518 intended for the treatment of androgen receptor (AR) positive triple-negative breast cancer granted Fast Track designation by the US FDA.

Jun 30 12:00 ET

Investor Relations Activity Record Form of Haichuang Pharmaceutical (June 17-26, 2024)

Jun 27 06:54 ET

Announcement on the plan of concentrated bidding reduction of shareholding by shareholders holding more than 5% of the shares

Jun 21 12:00 ET

Announcement on voluntary disclosure of clinical data for the PROTAC drug under development HP518 to be released at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 27 12:00 ET

Announcement on the resignation of senior management personnel and adjustment of core technical personnel

May 24 12:00 ET

CITIC Securities Co., Ltd.'s inspection opinion on the departure of core technicians of Haichuang Pharmaceutical Co., Ltd.

May 24 12:00 ET

Haichuang Pharmaceutical Investor Relations Activity Record Form (May 15 to May 21, 2024)

May 21 06:02 ET

Announcement on attending the 2023 Science and Technology Innovation Board Pharmaceutical Special Group Performance Briefing and the First Quarter 2024 Results Briefing

May 13 12:00 ET

Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders

May 10 12:00 ET

Legal Opinion of Beijing Junhe (Chengdu) Law Firm on the 2023 Annual General Meeting of Shareholders of Haichuang Pharmaceutical Co., Ltd.

May 10 12:00 ET

CITIC Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Haichuang Pharmaceutical Co., Ltd.

May 6 12:00 ET

2023 Annual General Meeting of Shareholders Meeting Materials

Apr 30 12:00 ET

2024 First Quarter Report

Apr 26 12:00 ET

CITIC Securities Co., Ltd.'s 2023 Continuous Supervision Site Inspection Report on Haichuang Pharmaceutical Co., Ltd.

Apr 25 12:00 ET

Report on the work of the Board of Supervisors for the year 2023

Apr 12 12:00 ET

Announcement on the company's 2024 related transaction forecast

Apr 12 12:00 ET

Special report on the storage and actual use of funds raised in 2023

Apr 12 12:00 ET

Announcement on adjustments to some initial public offering of shares

Apr 12 12:00 ET